Annexon, Inc.

NASDAQ:ANNX

Biotechnology

Healthcare
$3.52 -0.71%

-$0.04 today

Market cap
$576.73M
Beta
1.18
P/E (TTM)
-4.8
EPS (TTM)
-$1.01
52W Low $1.85High $7.18

Volume 2.98M

Average 2.56M

ANNX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Annexon, Inc.NASDAQ: ANNX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows in line with its trailing trend

Q1 FY2026 depreciation & amortization of $539K rose 0.4% year over year, behind the +0.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.4% toward the trailing-twelve-month pace of +0.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$539K-0.7% QoQ
Last fiscal yearDec 2025
$2.17M+0.7% YoY
LTMMar 2026
$2.17M+0.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year+0.7%——
3-year CAGR+0.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.17M USD
Year-over-year change
+0.7%
4-year CAGR
-10.8%

Depreciation & Amortization vs competitors

How ANNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.9% is the 5th highest of 11, against a peer median of -6.3%.
  • Over three fiscal years its annual growth of +0.9% compares with a peer median of +4.0%.
ANNX Competitors
Depreciation & Amortization for ANNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$10.17M USD-10.7%+6.1%9.7%
ALMSAlumis Inc. Common StockLTM Jun 2026$3.53M USD+5.4%+140.9%47.7%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.5M CHF+15.5%+0.4%69.9%
ANABAnaptysBio, Inc.LTM Mar 2026$2.43M USD+1.2%+1.2%1.0%
ANNXAnnexon, Inc.LTM Mar 2026$2.17M USD+0.9%+0.9%—
ABVXAbivax S.A.FY2025€1.07M EUR-2.5%+30.3%—
PRTAProthena Corporation plcLTM Mar 2026$856K USD+258.2%+6.4%1.5%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$528K USD-25.9%-17.1%6.3%
IMVTImmunovant, Inc.LTM Sep 2026$378K USD-10.0%+28.4%5.3%
IFRXInflaRx N.V.LTM Mar 2026€377.74K EUR-20.5%-12.3%1287.9%
QTTBQ32 Bio Inc.LTM Mar 2026$305K USD-36.9%+1.9%0.6%
Peer median (excluding ANNX) —-6.3%+4.0%6.3%

Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Depreciation & Amortization3.41M2.11M2.15M2.15M2.17M
Deferred Income Tax00000
Stock-Based Compensation018.52M18.18M19.43M16.42M
Change in Working Capital3.28M3.74M(5.81M)6.36M4.23M
Accounts Receivables00000
Inventory00000
Accounts Payables3.86M(287K)(2.08M)4.94M4.49M
Other Working Capital(575K)4.03M(3.73M)1.43M(261K)
Other Non-Cash Items17.52M1.28M(1.43M)(7.75M)(2.49M)
Operating Cash Flow(106.11M)(116.31M)(121.14M)(118.01M)(186.36M)
Capital Expenditures(1.65M)(6.53M)(193K)(15K)(137K)
Acquisitions (Net)0(64.97K)000
Purchases of Investments(225.6M)(113.2M)(108.09M)(583.93M)(212.21M)
Sales of Investments139.02M178.17M178.98M365.15M402.4M
Other Investing Activities064.97K000
Investing Cash Flow(88.24M)58.44M70.7M(218.8M)190.05M
Debt Repayment00000
Common Stock Issued1.8M130.48M135.51M161.87M110.47M
Common Stock Repurchased00000
Dividends Paid0000(1.86M)
Other Financing Activities0(7.57M)14K(665K)238K
Financing Cash Flow1.8M122.91M135.52M161.21M108.86M
Effect of Forex Changes(1.17M)1K5K(15K)2K
Net Change in Cash(193.72M)65.04M85.09M(175.61M)112.55M
Free Cash Flow(107.76M)(122.84M)(121.34M)(118.02M)(186.49M)

Annexon, Inc.

NASDAQ:ANNX

Intrinsic Alpha fair value

Locked

Current Price

$3.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.